$ANNX earnings report

Annexon reports Q3 2026 net loss of $51.2 million ($0.25 per share) with lower R&D spending, $213.4 million in cash and investments, and runway guided into 2028. AlphAI read Annexon's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readANNX · Q3 2026 · ended 2026-09-30

Annexon reports Q3 2026 net loss of $51.2 million ($0.25 per share) with lower R&D spending, $213.4 million in cash and investments, and runway guided into 2028

→Mixed quarter

The company reported no revenue and a net loss, with R&D expense down from $49.7 million to $41.4 million and net loss down from $54.9 million to $51.2 million. G&A rose from $7.3 million to $10.9 million, a $200 million credit facility was entered with $50 million drawn at closing, and the company says cash funds operations into 2028. Key value drivers (BLA submission, EMA review, ARCHER II Month 15 readout) are still pending.

EPS · GAAP
$(0.25)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development (R&D) expenses, Q3 2026GAAP$41.4M––
General and administrative (G&A) expenses, Q3 2026GAAP$10.9M––
Total operating expenses, Q3 2026GAAP$52.24M––
Loss from operations, Q3 2026GAAP−$52.24M––
Interest expense, Q3 2026GAAP−$833K––
Interest and other income, net, Q3 2026GAAP$1.85M––
Net loss, Q3 2026GAAP−$51.22M––
Net loss attributable to common stockholders, Q3 2026GAAP$51.2M––
Net loss per share, basic and diluted, Q3 2026GAAP$(0.25) per share––
Stock-based compensation, R&D, Q3 2026GAAP$2.63M––
Stock-based compensation, G&A, Q3 2026GAAP$2.48M––
Research and development (R&D) expenses, nine months 2026GAAP$123.7M––
General and administrative (G&A) expenses, nine months 2026GAAP$31.77M––
Total operating expenses, nine months 2026GAAP$155.5M––
Loss from operations, nine months 2026GAAP−$155.5M––
Interest expense, nine months 2026GAAP−$833K––
Interest and other income, net, nine months 2026GAAP$5.64M––
Net loss, nine months 2026GAAP−$150.7M––
Net loss attributable to common stockholders, nine months 2026GAAP−$150.7M––
Net loss per share, basic and diluted, nine months 2026GAAP$(0.75) per share––
Cash, cash equivalents and short-term investments, as of September 30, 2026other$213.4M––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The filing reports no equity financing in the quarter; the weighted-average share count rose to 204,652,743 for Q3 2026 from 149,123,701 for Q3 2025.

What drove it

  • The company states the R&D change is primarily associated with completed contract manufacturing expenses supporting tanruprubart regulatory filings, offset by continued development of vonaprument in GA.
  • The company states the G&A change reflects ongoing corporate consulting and professional services costs for the advancement of its registrational programs and compensation and personnel-related expenses.
  • Tanruprubart FORWARD data: 18 patients treated to date in the ongoing open-label U.S. and European study, with functional outcomes, complete target engagement and a generally well-tolerated safety profile observed, according to the company.
  • Vonaprument ARCHER II: all eligible patients have received at least 15 months of treatment with patient retention at 90%, and masked vision-loss events have tracked closely with projections, according to the company.
  • ANX1502: a completed proof-of-concept study in nine patients with cold agglutinin disease reported no significant safety signals and observed reductions in bilirubin and LDH, according to the company. Formulation optimization is underway.

Concerns

  • No revenue is reported for the quarter or the nine months, and the net loss continues in both periods.
  • Total stockholders' equity fell to $142,795 thousand from $211,648 thousand at December 31, 2025, and total liabilities rose to $107,613 thousand from $65,923 thousand.
  • The company drew $50 million on a new Oxford Finance facility; the remaining tranches depend on milestones or lender approval.
  • G&A expenses rose to $10.9 million from $7.3 million year over year, and G&A for nine months rose to $31,774 thousand from $24,110 thousand.
  • The filing's forward-looking statements list the final ARCHER II results, the ANX1502 formulation work and the ability to access the Oxford facility as risks.

What to watch

  • BLA submission for tanruprubart in GBS, expected in Q4 2026 per the filing.
  • EMA review of the tanruprubart MAA, which the filing describes as underway.
  • ARCHER II Phase 3 Month 15 single-study primary endpoint assessment by the independent DMC, expected in Q4 2026; the filing says the DMC may instead recommend continuing to Month 24.
  • If the DMC recommends the endpoint has been met, sub-study results are anticipated in Q1 2027, and ARCHER II completion including Month 24 analyses is expected in Q3 2027.
  • Achievement of milestones that would unlock the additional $100 million under the Oxford facility.
  • ANX1502 formulation optimization before studies in gMG and other neuromuscular disorders.

Balance sheet and cash flow

  • Cash and cash equivalents were $102,389 thousand at September 30, 2026, compared with $162,051 thousand at December 31, 2025.
  • Short-term investments were $110,985 thousand at September 30, 2026, compared with $76,294 thousand at December 31, 2025.
  • Term loan, non-current, was $49,340 thousand at September 30, 2026, compared with none printed at December 31, 2025.
  • Total assets were $250,408 thousand at September 30, 2026, compared with $277,571 thousand at December 31, 2025.
  • Total liabilities were $107,613 thousand at September 30, 2026, compared with $65,923 thousand at December 31, 2025.
  • Total stockholders' equity was $142,795 thousand at September 30, 2026, compared with $211,648 thousand at December 31, 2025.
  • The company entered into a strategic credit facility of up to $200 million with Oxford Finance LLC, drawing an initial $50 million at closing. An additional $100 million is available upon achievement of milestones related to the vonaprument and tanruprubart registrational programs, and the remaining $50 million is available subject to lender approval.
  • The company states that cash, cash equivalents and short-term investments of $213.4 million are expected to fund operations and anticipated milestones into 2028.
  • No operating cash flow, investing cash flow or free cash flow figures are printed in the filing.

Analysis

Annexon reported a third quarter 2026 net loss attributable to common stockholders of $51.2 million, or $0.25 per share, compared with $54.9 million, or $0.37 per share, a year earlier. The filing reports no revenue line. Operating expenses were $52,238 thousand, down from $57,018 thousand, with R&D falling to $41.4 million from $49.7 million while G&A rose to $10.9 million from $7.3 million. The company attributes the R&D change mainly to completed contract manufacturing for tanruprubart regulatory filings, partly offset by continued vonaprument development. For the nine months, R&D fell to $123,744 thousand from $142,039 thousand and G&A rose to $31,774 thousand from $24,110 thousand.

The balance sheet shows cash, cash equivalents and short-term investments of $213.4 million at September 30, 2026. Cash and cash equivalents were $102,389 thousand and short-term investments were $110,985 thousand, against $162,051 thousand and $76,294 thousand at December 31, 2025. Over the same period, total assets fell to $250,408 thousand from $277,571 thousand and stockholders' equity fell to $142,795 thousand from $211,648 thousand. A non-current term loan of $49,340 thousand appears on the balance sheet, consistent with the $50 million initial draw on the Oxford Finance facility described in the release. The company says the cash position is expected to fund operations and anticipated milestones into 2028.

On the pipeline, the company reports that 18 patients have been treated in the FORWARD study of tanruprubart in GBS and that a BLA submission with FORWARD data is expected in Q4 2026, while the EMA review of the EU MAA is underway. For vonaprument in GA, the ARCHER II Month 15 primary endpoint assessment by the independent DMC is expected in Q4 2026, with sub-study results anticipated in Q1 2027 if the endpoint is met, and completion including Month 24 analyses expected in Q3 2027. ANX1502 completed a proof-of-concept study in nine patients with cold agglutinin disease, and formulation work is ongoing before further studies.

Several figures are reported only as prose rounded to one decimal place, and the table values in thousands are used where both are printed. The net loss improvement comes from lower R&D spending in this period, while G&A and interest expense are higher, and the investment case rests on the pending regulatory and trial milestones named in the release.

Management, verbatim

Annexon is well-positioned for a transformative next 12 months, with multiple value-creating milestones expected across our differentiated upstream C1q platform

Douglas Love, President and Chief Executive Officer

In the third quarter, we advanced both programs, strengthened our balance sheet and added experienced leaders to our Board of Directors, advisory board, and team.

Douglas Love, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Revenue or collaboration income for Q3 2026 and nine months 2026: none reported in the filing.
  • Gross margin, cost of sales and segment data: not reported.
  • Prior-year and prior-quarter percentage changes for each line: not printed.
  • Prior-year figure for interest expense: the filing shows a dash for Q3 2025 and nine months 2025, which is left null.
  • Q2 2026 (prior-quarter) comparatives: not printed.
  • Operating, investing and free cash flow: not reported.
  • Formal financial guidance for 2026 or later: not provided in the filing.
  • Prior-year-end (December 31, 2025) comparatives for cash and short-term investments are printed on the balance sheet but not restated as yoy_change values.
  • Share repurchases or dividends: none reported.
  • The previous outlook covered funding into 2028 and milestone timing only, with no quantified guidance for a metric reported in this quarterly release.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readANNX · Second Quarter 2026 · ended June 30, 2026

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

→Mixed quarter

Annexon reported increased R&D and G&A expenses and a higher net loss, while strengthening liquidity through a credit facility and advancing several clinical and regulatory milestones.

EPS · GAAP
$0.28

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development (R&D) expensesGAAP$46.6M––
General and administrative (G&A) expensesGAAP$10.6M––
Net loss attributable to common stockholdersGAAP$55.3M––
Net loss per shareGAAP$0.28 per share––
Cash, cash equivalents and short-term investmentsother$209.2M––

into 2028 outlook

  • NoteCash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028.
  • NoteBiologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.
  • NoteMonth 15 primary endpoint on track for the fourth quarter of 2026.
  • NoteFinal trial completion, including the Month 24 primary endpoint expected in the third quarter of 2027.
  • NoteUpdate on POC trial in CAD anticipated in the Fall of 2026.

What drove it

  • R&D expense change was primarily associated with the Phase 3 ARCHER II trial of vonaprument in GA and contract manufacturing expenses of product candidates.
  • G&A expense change reflected ongoing corporate consulting and professional services costs for advancement of registrational programs.
  • Early improvement in strength and clinically meaningful reduction in disability were reported in the first ten U.S. and European patients with GBS from the ongoing open-label FORWARD study.
  • The EU Marketing Authorisation Application for tanruprubart is under review with the European Medicines Agency.
  • All eligible patients in the global Phase 3 ARCHER II trial have received at least 12 months of treatment, with masked event accrual consistent with projected timelines.
  • Vonaprument was described as generally well-tolerated, with a low discontinuation rate (<10%) and high compliance (>95%).

Concerns

  • Net loss attributable to common stockholders was $55.3 million, compared to $49.2 million for the quarter ended June 30, 2025.
  • R&D expenses were $46.6 million, compared to $44.2 million for the quarter ended June 30, 2025.
  • G&A expenses were $10.6 million, compared to $7.6 million for the quarter ended June 30, 2025.
  • The BLA submission, ARCHER II primary-endpoint results, and ANX1502 proof-of-concept update remain anticipated future milestones rather than reported outcomes.
  • The company cited risks including final Phase 3 ARCHER II results, ability to obtain necessary capital, potential clinical-trial delays, regulatory acceptance of clinical data, and ability to obtain regulatory approval and commercialize product candidates.

What to watch

  • Biologics License Application submission with U.S./European data from the FORWARD trial expected in fourth quarter of 2026.
  • Month 15 primary endpoint from the Phase 3 ARCHER II trial on track for the fourth quarter of 2026.
  • ANX1502 proof-of-concept trial update in cold agglutinin disease anticipated in the Fall of 2026.
  • Final ARCHER II trial completion, including the Month 24 primary endpoint, expected in the third quarter of 2027.
  • Execution against the stated operating runway into 2028 following the initial draw under the credit facility.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $209.2 million as of June 30, 2026.
  • Entered into a strategic credit facility of up to $200 million with Oxford Finance LLC.
  • Initial $50 million drawn at closing.
  • Current cash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028.

Analysis

Annexon remains a clinical-stage company in an execution-heavy period, with the quarter defined by pipeline milestones rather than reported commercial revenue. The company highlighted early strength improvement and clinically meaningful disability reduction in the first ten U.S. and European patients in the open-label FORWARD GBS study. Its EU Marketing Authorisation Application is under review, and it expects a BLA submission supported by U.S./European FORWARD data in the fourth quarter of 2026.

Investment in the pipeline increased. R&D expenses were $46.6 million, compared to $44.2 million for the quarter ended June 30, 2025, primarily tied to the Phase 3 ARCHER II trial of vonaprument and contract manufacturing. G&A expenses were $10.6 million, compared to $7.6 million, reflecting corporate consulting and professional services supporting registrational programs. Net loss attributable to common stockholders was $55.3 million, compared to $49.2 million.

The GA program added strategic scope during the quarter. ARCHER II retained its Month 15 primary endpoint while adding a Month 24 dual primary endpoint, allowing success at either independent efficacy timepoint. All eligible patients have received at least 12 months of treatment, and the company said masked event accrual remains consistent with projected timelines. The Month 15 endpoint is on track for the fourth quarter of 2026, while final completion including the Month 24 endpoint is expected in the third quarter of 2027. Annexon also launched an open-label extension study for longer-term safety and benefit evaluation.

Liquidity is a central positive offset to the operating loss. Cash, cash equivalents and short-term investments were $209.2 million as of June 30, 2026. The company also entered a credit facility of up to $200 million, with an initial $50 million drawn at closing, and stated that current liquidity plus credit-facility funds are expected to fund operations and anticipated milestones into 2028. No prior-quarter financial comparison was reported, so quarter-over-quarter changes in expenses, loss, and liquidity cannot be assessed from the filing.

The near-term read is therefore driven by clinical and regulatory execution. Investors will focus on the expected fourth-quarter 2026 BLA submission for tanruprubart, the ARCHER II Month 15 primary endpoint, and the Fall 2026 ANX1502 proof-of-concept update. The release did not report topline efficacy data from ARCHER II, nor did it provide financial revenue or expense guidance beyond the stated runway.

Management, verbatim

2026 is a defining year for our company, with meaningful progress across both our Guillain-Barré syndrome (GBS) and geographic atrophy (GA) programs that position us to potentially deliver two transformative therapies for millions of patients in need.

Douglas Love, president and chief executive officer of Annexon

With our leadership capabilities and financial position strengthened, we are entering an exciting period of execution, with multiple important clinical and regulatory milestones expected over the next 6 to 12 months and a significant opportunity to create value for patients and stakeholders.

Douglas Love, president and chief executive officer of Annexon

Not in the filing

stated, not guessed
  • Total revenue and prior-year, prior-quarter, year-over-year, and quarter-over-quarter revenue comparisons were not reported in the provided text.
  • Segment revenue and segment growth comparisons were not reported.
  • Gross profit, gross margin, operating income or loss, and operating margin were not reported in the provided text.
  • Non-GAAP financial measures were not reported.
  • Operating cash flow, free cash flow, capital expenditures, and cash-flow comparisons were not reported.
  • Debt balance, interest expense, and repayment terms were not reported. The filing reported only a credit facility of up to $200 million and an initial $50 million draw.
  • Share repurchases, dividends, and other capital-return activity were not reported.
  • Prior-quarter figures and quarter-over-quarter changes for R&D expenses, G&A expenses, net loss, net loss per share, and cash were not reported.
  • Year-over-year percentage changes for R&D expenses, G&A expenses, net loss, and net loss per share were not reported.
  • Financial revenue, gross-margin, operating-expense, and tax-rate guidance were not reported.
  • Prior-quarter outlook was not provided, so comparison of actual results with prior guidance was not available.
  • The filing text was truncated before the condensed consolidated statements of operations tables, so any additional line items in those tables were not available for verification.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ANNX earnings dates

When is Annexon's next earnings date?
AlphAI has no date for ANNX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.